AI Investments | CCS Medical

Unique AI Capabilities

Supplies were just the start. CCS stands alone in the diabetes distribution industry as the only organization to envision, build, and deploy enterprise-level agentic AI. Over four years ago, CCS made the commitment to advance patient care and operational excellence by integrating AI technologies and unique Small Language Models to streamline workflows and deliver better outcomes, setting a new standard for the industry. Developed through extensive investment and innovation, every model trained and every workflow reimagined has been built with one person in mind: the patient. Akin to a brain, these models allow CCS to interact with individuals in a very natural way that enables real autonomous engagement.

CeeCee™: Pioneering Agentic AI

CCS built CeeCee™ — a chronic care management agentic AI. Leveraging sophisticated models across an extensible platform, CeeCee acts autonomously to streamline patient engagement, provider workflows, and operational decision-making with unmatched speed and efficiency.

Unlike traditional automation, CeeCee proactively interacts with patients and providers — anticipating needs rather than simply reacting to them. By automating routine tasks and communications while dynamically adapting to individual patient profiles, CeeCee delivers personalized, timely support at every touchpoint. The result is a smarter, more responsive distribution network: labor-intensive steps in the patient journey are streamlined, support teams are freed to focus on what matters most, and every patient receives the attention their condition demands.

We're Not Just Ahead of the Curve. We're Building It.

“CCS is demonstrating a truly innovative approach to AI in healthcare. By deploying a sophisticated multi-agent network across its entire operation, CCS is transforming how complex patients are supported—autonomously handling interactions, accelerating care delivery, and improving operational efficiency.” - Bill Fera, MD, GenAI Health and Life Sciences Lead at Deloitte

PropheSee™: Predictive Analytics and Intervention Platform

PropheSee™ is CCS’s proprietary predictive analytics platform — purpose-built to get ahead of the moments that matter most in a patient’s diabetes journey. By synthesizing more than 800 attributes, including Social Determinants of Health and real-time signals, PropheSee forecasts the likelihood of an individual discontinuing CGM therapy with 85% accuracy within a 30-day forward window. But prediction is only half the story. PropheSee acts — delivering personalized interventions mapped to unique personas before disengagement ever occurs.

The impact speaks for itself: a 50% improvement in test versus control outcomes and $10M saved within the Medicare fee-for-service population alone. Recognized as a best-in-class approach to transforming diabetes care, PropheSee doesn’t just analyze data — it turns it into the right action, for the right patient, at the right time.

Learn More